iosBio is developing OraPro-COVID-19, a self-administered oral vaccine candidate against coronavirus AND AXIM’s novel #VBP is approximately 10 times more potent and stable than current VBP options on the market

 

https://finance.yahoo.com/news/stabilitech-biopharma-announces-name-change-060000239.html

iosBio is developing OraPro-COVID-19, a self-administered oral vaccine candidate against coronavirus.

Administered orally in a capsule, OraPro-COVID-19 uses a non-replicating adenovirus-5 viral vector with the SARS-CoV-2 spike-protein as its payload, delivered straight to the lymphoid tissues of the gut, where it delivers multiple levels of immunity.

[NOT injected?! I like that.] #OraPro

+++

https://www.biospace.com/article/releases/axim-biotechnologies-files-patent-for-virus-binding-recombinant-protein-for-sars-cov-2-covid-19-and-begins-manufacturing/

Initial tests show that AXIM’s novel #VBP is approximately 10 times more potent and stable than current VBP options on the market.

“By internally developing and manufacturing this virus binding protein, AXIM’s COVID-19 research team no longer needs to rely on outside protein supply to continue our research and can greatly cut down on our research costs.

We are now able to make the quantities needed for our current and future COVID-19 products, including

COVID-19 rapid neutralizing antibody diagnostic #tests,

the first-ever face #masks that capture and deactivate SARS-CoV-2 and more,”

said AXIM® Biotech CEO John W. #Huemoeller II.

#SARSCoV2